On the Edge, at times, reads like multiple books stuffed into one giant one. Many of its subparts deserve even fuller treatment of their own, and Silver acknowledges that certain sections were ...

But in the last few years, with the approval of GLP-1 drugs like Wegovy and Zepbound, more and more people are opting for obesity medicines over gold-standard surgical treatments. “On a ...

If employees are asking about GLP-1 coverage — in pursuit of general weight loss, not just to treat diabetes — HR may need a plan. At a recent Digital Health New York session titled “The ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their ...

Among the findings, the report published Monday highlights the impact of Ozempic, other GLP-1 drugs and hormones used in gender-affirming care and lays out sex- and gender-specific risks of stroke.

Could these medications — collectively known as GLP-1 receptor agonists — also fight America’s most difficult drug problems? Striking new data suggests they might. On Thursday, the journal ...

The company benefits from GLP-1 drug sales and is positioned for high margins and recurring revenues in the growing healthcare market. HIMS achieved positive operating income with 50% revenue ...

A new study suggests that GLP-1 agonist medications like Ozempic, which are used for diabetes management and weight loss, may help reduce the risk of overdose and alcohol intoxication in people ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Neu­ro­gas­trx be­lieves its drug could treat one of the most trou­ble­some side ef­fects of one of the in­dus­try’s biggest block­busters.

When GLP-1 medications were first introduced for obesity, they took off like wildfire. It was all over social media and really the press. Basically, everybody wanted to get their hands on them.